Scientists report long-term gantenerumab use might prevent cognitive decline in people with genetic predisposition to ...

Alzheimer's disease progresses gradually, with subtle behavioral changes often appearing long before a formal diagnosis.

The number of cases will increase, but the rates seem to be declining with every birth cohort that reaches advanced ages, ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

At the centre of this discovery is a previously unknown protein, ArfGAP2, which plays a key role in triggering immune ...

Aging brains may struggle to clear out waste, contributing to memory loss and diseases like Alzheimer’s. But researchers have now found that improving the brain’s waste-draining vessels in old mice ...

Panelists discuss how significant knowledge gaps among nonspecialist providers—particularly regarding differential diagnosis, interpretation of cognitive assessments, and awareness of treatment ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains<a class="excerpt-read-more" href=" More ...

Leqembi is an infusion therapy that targets and removes the beta-amyloid plaque that builds up in the brains of Alzheimer's patients.

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...

The Alzheimer’s Disease Research Center (ADRC) at the University of Pittsburgh is one of the country’s hubs for researchers ...

An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in ...